Song Jie, Yang Bing, Jia Xiaobin, Li Mingyu, Tan Wei, Ma Shitang, Shi Xinhong, Feng Liang
School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.
Affiliated Hospital on Integration of Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Front Endocrinol (Lausanne). 2018 Nov 29;9:724. doi: 10.3389/fendo.2018.00724. eCollection 2018.
Dysregulation of metabolic pathways leads to type 2 diabetes, characteristic of high glucose concentration caused by insulin resistance. The histone deacetylases sirtuins exhibit remarkable enzymatic activities. Accumulating evidence indicates that sirtuins can be pharmacologically activated to ameliorate diabetes. Here, we evaluated different roles of sirtuins (SIRT1-SIRT7) in diabetes progression and described their involvement in metabolic pathways of skeletal muscle, adipose tissue and liver. The nuclear sirtuins, SIRT1, SIRT6, and SIRT7, regulate the activity of key transcription factors and cofactors in almost all tissues with the cellular responses to energy demands. The mitochondrial sirtuins, SIRT3, SIRT4, and SIRT5, regulate the activity of mitochondrial enzymes in response to fasting and calorie restriction. Moreover, genetic polymorphisms of SIRT1 and SIRT2 have been reported to associate with diabetes development. It's worth noting that SIRT1, SIRT2, SIRT3, and SIRT6 are positive regulators of insulin resistance in most cases. In the opposite, SIRT4 and SIRT7 inhibit insulin secretion and fatty acid oxidation. Identification of SIRT1 activators for diabetes has gained wide attention, such as metformin, resveratrol, and resveratrol derivatives. Randomized, prospective, and large-scale clinical trials are warrant to uncover the responsibilities of SIRTs modulators on diabetes progress.
代谢途径失调会导致2型糖尿病,其特征是由胰岛素抵抗引起的高血糖浓度。组蛋白去乙酰化酶sirtuins具有显著的酶活性。越来越多的证据表明,sirtuins可以通过药物激活来改善糖尿病。在此,我们评估了sirtuins(SIRT1-SIRT7)在糖尿病进展中的不同作用,并描述了它们在骨骼肌、脂肪组织和肝脏代谢途径中的参与情况。细胞核中的sirtuins,即SIRT1、SIRT6和SIRT7,在几乎所有组织中调节关键转录因子和辅助因子的活性,以应对细胞对能量的需求。线粒体中的sirtuins,即SIRT3、SIRT4和SIRT5,响应禁食和热量限制调节线粒体酶的活性。此外,据报道SIRT1和SIRT2的基因多态性与糖尿病的发生有关。值得注意的是,在大多数情况下,SIRT1、SIRT2、SIRT3和SIRT6是胰岛素抵抗的正调节因子。相反,SIRT4和SIRT7抑制胰岛素分泌和脂肪酸氧化。寻找用于治疗糖尿病的SIRT1激活剂已受到广泛关注,如二甲双胍、白藜芦醇和白藜芦醇衍生物。需要进行随机、前瞻性和大规模的临床试验,以揭示SIRTs调节剂在糖尿病进展中的作用。